The Accelerating Leading-edge Science (ALS^²) is a new program to spur innovative research on amyotrophic lateral sclerosis (ALS), a progressive and fatal neurological disease that weakens and eventually destroys voluntary muscles.

ALS^² will be part of the NIH Common Fund’s High-Risk, High-Reward (HRHR) research program. The four initiatives of the HRHR program are a time-tested, powerful approach to sparking innovation. They support exceptionally creative research that has the potential to transform biomedical science. NIH will apply this potential to ALS^² through the HRHR program’s Transformative Research Award initiative.

Read more in the press release.